ISIC C21 · United Kingdom · 2 publishers
Pharmaceuticals in United Kingdom
14 verified figures for United Kingdom, covering 13 indicators from 2 primary sources. Every figure links to the report it came from.
The short version
Key takeaways
Market size and output 4
- Pharmaceutical direct gross value added in the United Kingdom was 20.4 billion GBP (ABPI, published 8 September 2026). ABPI ↗ T2 Official
- Pharmaceutical industry investment commitments in the United Kingdom were 2 billion GBP between 1 September 2025 and 8 September 2026 (ABPI). ABPI ↗ T2 Official
- Pharmaceutical business enterprise research and development expenditure in the United Kingdom was 8.7 billion GBP in 2023 (ONS). ONS ↗ T1 Official
- Branded medicines sales clawback cap in the United Kingdom was 15% (ABPI, published 8 September 2026). ABPI ↗ T2 Official
People and employment 2
Adoption and share 1
- Innovative medicines spending target share of GDP in the United Kingdom was 0.6% (ABPI, published 8 September 2026). ABPI ↗ T2 Official
Other measures 3
- Median drug approval time in the United Kingdom was 378 days in 2025 (ABPI). ABPI ↗ T2 Official
- Clinical trials regulatory approval timeliness rate in the United Kingdom was 98% (ABPI, published 8 September 2026). ABPI ↗ T2 Official
- Newer medicines clawback rate in the United Kingdom was 22.9% in 2025 (ABPI). ABPI ↗ T2 Official
The complete table
Pharmaceuticals data for United Kingdom
Every row links to its own page with the full source, verbatim quote and citation.
14 data points across 13 indicators. Each line shows the latest value; open a line for earlier periods and forecasts.
Branded medicines sales clawback capas of 8 Sep 202615%ABPIT22026actual→
Clinical trial patient recruitment changeApril 2022 – March 2025-25%ABPIT22025actual→
Clinical trials regulatory approval timeliness rateas of 8 Sep 202698%ABPIT22026actual→
Innovative medicines spending target share of GDPas of 8 Sep 20260.6%ABPIT22026actual→
Median drug approval time (count)+1 more2025378 daysABPIT22025actual→
New medicines availability rate2021–202433%ABPIT22024actual→
Newer medicines clawback rate202522.9%ABPIT22025actual→
Pharmaceutical business enterprise research and development expenditure20238.7 billion GBPONST12023estimate→
Pharmaceutical direct gross value addedas of 8 Sep 202620.4 billion GBPABPIT22026actual→
Pharmaceutical industry employmentas of 8 Sep 2026125,000ABPIT22026actual→
Pharmaceutical industry investment commitments1 Sep 2025 to 8 Sep 20262 billion GBPABPIT22026actual→
Projected pharmaceutical direct gross value added203533.4 billion GBPABPIT22035forecast→
Projected pharmaceutical employment2035200,000ABPIT22035forecast→
Primary documents
Sources
| Document | Publisher | Authority tier | Accessed | Locator | Data points |
|---|---|---|---|---|---|
| Business enterprise research and development, UK Press release | ONS | T1 Official | 17 Sep 2026 | Main points | 1 |
| Green shoots for UK pharma investment, but delivery will decide whether they take root Press release | ABPI | T2 Official | 17 Sep 2026 | UK competitive weaknesses; UK areas of unrealised potential; Green shoots for UK pharma investment, but delivery will decide whether they take root | 13 |
Report snapshots are retained internally for verification only and are never redistributed. Where a figure comes from a paywalled report, only the number published in its public summary is recorded.
All 14 collected records for United Kingdom are published as verified.
Cite & reuse
Cite this page
Data on this page is published under CC BY 4.0. You may reuse it, including commercially, provided you attribute it. Each figure's own page carries APA, MLA, Chicago and BibTeX citations naming its original publisher.
StatOrigin. (2026). Pharmaceuticals in United Kingdom: statistics. Retrieved from https://statorigin.org/industries/pharmaceuticals/united-kingdom